NABI /DE/
424B3, 1996-11-27
BIOLOGICAL PRODUCTS, (NO DIAGNOSTIC SUBSTANCES)
Previous: NICHOLAS FUND INC, NSAR-A, 1996-11-27
Next: IAI INVESTMENT FUNDS VII INC, NSAR-A, 1996-11-27



<PAGE>
 
PROSPECTUS SUPPLEMENT                           Filed pursuant to Rule 424(b)(3)
To Prospectus Dated May 3, 1996,                       Registration No. 333-2253
As Supplemented to Date

                                  $80,500,000

                                     NABI

                6 1/2% Convertible Subordinated Notes due 2003
                                      and
               Shares of Common Stock, Par Value $.10 Per Share,
                       Issuable Upon Conversion Thereof

     This Prospectus Supplement (the "Supplement") relates to the resale be 
Robertson Stephens & Co. LLC ("Robertson Stephens") of up to $510,000 aggregate 
principal amount of 6 1/2% Convertible Subordinated Notes due 2003 (the "Notes")
of NABI, a Delaware corporation (the "Company"), originally issued in private 
placements consummated on February 7 and March 6, 1996 (the "Debt Offering"), 
pursuant to NABI's Registration Statement on Form S-3 (No. 333-2253) (the 
"Registration Statement"). This Supplement should be read in conjunction with 
the Prospectus dated May 3, 1996, as supplemented to date (the "Prospectus"), to
be delivered with this Supplement. All capitalized terms used but not defined in
this Supplement shall have the meanings given them in the Prospectus.

     Based on information provided to the Company, the aggregate principal 
amount of the Notes that are currently beneficially owned by Robertson Stephens
is $510,000, all of which may be sold at this time pursuant to the Prospectus as
supplemented hereby. Robertson Stephens was an initial purchaser of the Notes in
the Debt Offering, in connection with which Robertson Stephens received
customary compensation for its services. Additional information concerning the
Selling Securityholders (including Robertson Stephens) may be set forth from
time to time in additional supplements to the Prospectus. The total outstanding
aggregate principal amount of the Notes is $80,500,000.

     The closing price of the Company's Common Stock as reported on The Nasdaq 
National Market on November 22, 1996 was $9.50 per share.

     The Notes will be subordinated to all existing and future Senior 
Indebtedness of the Company. At August 23, 1996, Senior Indebtedness was
approximately $6,300,000. The Indenture contains no limitations on the
incurrence of additional indebtedness or other liabilities by the Company.

     The Notes are neither listed on a national securities exchange nor quoted
on an automated quotation system. However, the Notes are eligible for trading
in the Private Offerings, Resales and Trading through Automated Linkages
("PORTAL") Market. Notes are sold pursuant to the Registration Statement will no
longer be eligible for trading in the PORTAL Market.

         The date of this Prospectus Supplement is November 25, 1996. 

















© 2022 IncJournal is not affiliated with or endorsed by the U.S. Securities and Exchange Commission